Company Focus
Novo Nordisk
Latest Novo Nordisk News
Generics
Russia is currently experiencing a boom in the sales of Ozempic (semaglutide) and its analogues due to a high demand for such drugs among domestic customers, reports The Pharma Letter’s local correspondent. 5 August 2025
Related News
Insights
Company Spotlight
A privately-held biotech company developing multiple-dose gene therapies to treat patients with genetic and idiopathic diseases, focusing first on hemophilia B.
Latest News & Features of interest to Novo Nordisk
Pharmaceutical
Pfizer posted second-quarter 2025 earnings and revenue that exceeded analyst estimates and raised its full-year profit outlook, pushing its shares higher by 4% in Tuesday morning’s trading. 5 August 2025
Pharmaceutical
US biopharma Vertex Pharmaceuticals has reported its financial results for the second quarter of 2025 and reiterated full year financial guidance. 5 August 2025
Generics
Russia is currently experiencing a boom in the sales of Ozempic (semaglutide) and its analogues due to a high demand for such drugs among domestic customers, reports The Pharma Letter’s local correspondent. 5 August 2025
Biotechnology
US cardiometabolic specialist MetaVia has announced a research collaboration with Korea’s Syntekabio, an artificial intelligence (AI)-driven drug discovery company. 5 August 2025
Biotechnology
Japanese drugmaker Sumitomo Pharma Company and Tokyo-based Racthera announced that on August 5, they had submitted an application of manufacturing and marketing authorization for allogeneic iPS cell-derived dopaminergic neural progenitor cells (generic name: raguneprocel) indication of the improvement of motor functions during the off-time period of patients with advanced Parkinson’s disease. 5 August 2025
Pharmaceutical
Digital healthcare company Noom has made a move in the US weight loss market. 5 August 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), extending its use as monotherapy along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. 4 August 2025
Biotechnology
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate slowing of decline, with most participants having completed treatment, US pharma major Eli Lilly announced today. 4 August 2025
Pharmaceutical
Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective August 7, 2025. Mr Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective August 7. 4 August 2025
Biotechnology
National Health Service (NHS) England has agreed to commission the use of Hemlibra (emicizumab) as a prophylactic treatment for patients of all ages with moderate hemophilia A with a severe bleeding phenotype who do not have factor VIII inhibitors. 2 August 2025
Latest In Brief for Novo Nordisk
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Related Ones To Watch News
Last week, a US Food and Drug Administration (FDA) advisory committee (AdCom) voted against approval of Danish drugmaker Lundbeck and Japan-based Otsuka’s Rexulti for post-traumatic stress disorder. France’s Sanofi announced it is expanding its respiratory vaccines pipeline with an up to $1.6 billion acquisition of UK biotech Vicebio. French biotech Abivax released new Phase III data on its investigational ulcerative colitis candidate obefazimod that saw its shares nearly quadruple. Also of note was the latest setback for Sarepta’s Duchenne muscular dystrophy drug Elevidys, when the European Medicines human health committee, the CHMP, declined partner Roche’s accelerated approval of the drug. 27 July 2025
17 June 2025
16 June 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze